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ABSTRACT
The transcription factor (TF) SOX18 drives lym-
phatic vessel development in both embryogenesis
and tumour-induced neo-lymphangiogenesis. Ge-
netic disruption of Sox18 in a mouse model pro-
tects from tumour metastasis and established the
SOX18 protein as a molecular target. Here, we re-
port the crystal structure of the SOX18 DNA binding
high-mobility group (HMG) box bound to a DNA el-
ement regulating Prox1 transcription. The crystals
diffracted to 1.75Å presenting the highest resolution
structure of a SOX/DNA complex presently available
revealing water structure, structural adjustments at
the DNA contact interface and non-canonical confor-
mations of the DNA backbone. To explore alterna-
tives to challenging small molecule approaches for
targeting the DNA-binding activity of SOX18, we de-
signed a set of five decoys based on modified Prox1-
DNA. Four decoys potently inhibited DNA binding of
SOX18 in vitro and did not interact with non-SOX TFs.
Serum stability, nuclease resistance and thermal de-
naturation assays demonstrated that a decoy circu-
larized with a hexaethylene glycol linker and termi-
nal phosphorothioate modifications is most stable.
This SOX decoy also interfered with the expression
of a luciferase reporter under control of a SOX18-
dependent VCAM1 promoter in COS7 cells. Collec-
tively, we propose SOX decoys as potential strat-
egy for inhibiting SOX18 activity to disrupt tumour-
induced neo-lymphangiogenesis.
INTRODUCTION
SRY-related box 18 (SOX18) belongs to the SOX transcrip-
tion factor (TF) family comprising 20 paralogous mem-
bers in the human genome with critical but diverse roles
in specifying and maintaining cellular identities through-
out development (1–4). DNA recognition is accomplished
by a 79 amino acid high mobility group (HMG) box.
The HMG box is ubiquitously found in a large number
of DNA binding proteins that bind DNA either specifi-
cally or non-specifically (5). The HMG box of SOX pro-
teins confers sequence specificity and all members bind to
a short (A/T)2T3T4G5T6 core sequence with high affinity
(6,7). Yet, high-throughput studies suggest subtle variations
within the core and flanking regions that could demarcate
preferred recognition sequences of individual SOX family
members (6,8). The Sox DNA motif is short and degener-
ated and therefore highly abundant in the human genome.
Thus, it remains an open question how individual SOX pro-
teins select specific sets of target genes to dictate cell fate
decisions. An in depth understanding how target DNA se-
lectivity is achieved would also inform efforts for the design
of nucleic acid-based drugs. To aid these goals we explored
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in this study the DNA binding mechanism of SOX18 for its
purported role in the metastasis of solid tumours.
SOX18 regulates angiogenesis (9), lymphangiogenesis
(10) and hair follicle differentiation (11). In mice, SOX18
is expressed at 9 days post coitum (dpc) in a subpopulation
of endothelial cells from the anterior cardinal vein and in-
duces a lymphatic endothelial cell (LEC) fate which sub-
sequently gives rise to the initial lymphatic vascular plexus
(10). SOX18 binds to and causes the transactivation of the
Prospero homeobox 1 (Prox1) gene, the hallmark of LEC
identity. In Sox18 as well as Prox1 loss of function sce-
narios, deficient mice are devoid of lymphatic vessels, de-
velop severe generalized edema and die in utero at around
14.5 dpc (10,12). The regulatory cascade from SOX18 to
Prox1 is therefore regarded as a key regulatory switch con-
ferring lymphatic cell specification (reviewed in (13,14)).
Reminiscent to its role in the early embryo, SOX18 also
initiates the formation of new lymphatic vasculature (neo-
lymphangiogenesis) in mouse melanoma models (15). Gene
targeted deletion of Sox18 has been shown to interfere with
tumour-induced lymphangiogenesis and SOX18 was there-
fore proposed as a novel molecular target to prevent the
metastatic spread of solid tumours (16). In human, SOX18
was implicated as prognostic marker of poor patient out-
come for solid tumours such as gastric cancer, breast ade-
nocarcinoma and non-small cell lung cancer (17–19). With
the view to manipulating SOX18 activity in a therapeutic
setting, here we explore a way to inhibit the function of this
TF. As the DNA binding domains of TF proteins are widely
deemed ‘undruggable’ using small-molecules (20,21), alter-
native strategies need to be considered to make this target
class accessible for cancer therapy (22). We therefore set out
to structurally analyse the DNA recognition by SOX18 and
to utilize these insights to design SOX DNA decoys for its
selective inhibition of gene transactivation.
Published structural data of SOX/DNA complexes are
available for SRY (23), SOX2 (24,25), SOX17 (26) and
SOX4 (27) greatly improved our understanding of SOX
DNA recognition. Yet, these structures were built using
data at intermediate resolution regimes with a 2.4Å struc-
ture of the SOX4/DNA complex providing the highest res-
olution dataset. To further analyse how SOX TFs in gen-
eral and SOX18 in particular engage their target genes, we
solved the crystal structure of SOX18-HMG bound to a
16 bp regulatory region derived from an intron of its tar-
get gene Prox1 using crystals diffracting to 1.75Å resolu-
tion. We used the Prox1-DNA to design SOX decoys and
tested their potency, selectivity, stability as well as their ef-
fects on the expression of SOX18 target genes in cell cul-
ture. This approach led to the identification of a pan-SOX
inhibitory decoy. This SOX-HMG family specific decoy
shows prolonged resistance to nuclease digestion, degrada-
tion in mouse serum and thermal denaturation. Further, it
inhibits the expression of SOX18 dependent reported genes.
MATERIALS AND METHODS
Production of SOX18-HMG for crystallization
The pENTR-mSOX18-HMG entry clone encoding
79 amino acids of the HMG box of mouse SOX18
(accession BC006612) was generated by GATEWAY





portion underlined) containing attB sites and a 5′ tobacco
etch virus (TEV) protease cleavage site. The SOX18-
HMG box was recombined by GATEWAY LR into the
pDESTHisMBP plasmid and heterologously expressed in
BL21 (DE3) cells and purified as described previously (28).
In brief, the fusion protein was purified using an immo-
bilized metal affinity chromatography step, tag cleavage
achieved using TEV protease followed by ion exchange and
size exclusion chromatography (Figure 1A).
Crystallization and data collection
A solution of polyacrylamide gelelectrophoresis (PAGE)-
purified 16 bp Prox1-DNA elements with CG-overhangs
(5′-CACTAGCATTGTCTGGG-3′) was obtained from
Sigma-Proligo at 1 mM and adjusted to pH 8.0 using Tris–
HCl. Annealing was carried out by first combining equimo-
lar amounts of complementary DNA, followed by heating
to a temperature of 95◦C for 5 min and cooling to 4◦C at the
rate of 0.5◦C/s using a polymerase chain reaction (PCR)
thermocycler (Bio-Rad). The protein/DNA complex was
prepared by mixing SOX18-HMG (79 aa) and Prox1-DNA
at a molar ratio of 1:1.2. The complex was concentrated to
15 mg/ml using a Vivaspin centrifugal filter column with
molecular weight cut-off of 3 kDa (Sartorius). A buffer
containing 0.1 M DL-Malic acid, MES monohydrate, Tris
(MMT), pH 5.0, 25% (w/v) PEG1500 was used to grow
crystals at ambient temperature in a hanging–drop vapour
diffusion setting. A drop volume of 1 l was soaked with
1 l of soaking–solution (1 % dimethyl sulfoxide (DMSO),
0.62 mM compound, 0.1 M MMT buffer pH 5.0, 25% (w/v)
PEG1500). The cryoprotectant used consisted of 0.1 M
MMT buffer pH 5.0, 25% (w/v) PEG1500 plus 15% (w/v)
glycerol. Crystals were flash frozen in liquid nitrogen. A
1.75Å resolution data set was collected at the X29 beam-
line of the National Synchrotron Light Source (Upton NY)
and processed using the HKL–2000 software (29) (Supple-
mentary Table S1).
Structure solution and refinement
The search model for molecular replacement was pre-
pared using the coordinates of the crystal structure of
the SOX4/Lama1-DNA complex (PDB ID: 3U2B (27)).
Molecular replacement was performed with phaser (30) us-
ing data from 50Å to 1.75Å searching for one protein/DNA
complex in the asymmetric unit by including space groups
P64 and P62. Phaser found one solution in space group P64
and a first Fourier difference electron density map revealed
new interpretable features, confirming the correctness of the
solution. The model was built manually using Coot (31)
by interpreting 2Fo-Fc and Fo-Fc electron density maps.
Refinement was performed with Phenix.refine (32) includ-
ing a simulated annealing run at the beginning of refine-
ment. 5% of the reflections were marked for cross-validation
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ing Phenix.refine. The final rounds included translation-
libration-screw refinement.
Isothermal titration calorimetry (ITC)
A 15-bp Prox1-DNA element (5′- CTAG-
CATTGTCTGGG; Life Technologies) was annealed
in 1× annealing buffer (20 mM Tris–HCl, pH 8.0; 50 mM
MgCl2; 50 mM KCl) as described above. The isothermal
titration calorimetry (ITC) experiment was carried out in
degassed ITC buffer containing 10 mM potassium phos-
phate, 150 mM KCl, pH 7.0. Prox1-DNA was extensively
dialysed against 2× 1 l of degassed ITC buffer with 3.5K
MWCO Snakeskin Dialysis Tubing (Life Technologies) at
4◦C. The dialysate was replaced after 2 h and dialysis was
continued overnight. For buffer exchange of SOX18-HMG
(79 aa), a batch of freshly purified protein was applied
to a Superdex S75 16/60 column equilibrated in ITC
buffer and peak fractions were concentrated up to 70
M, flash-frozen and stored at −80◦C. Reactants were
concentrated with Nanosep 3K MWCO OMEGA spin
tubes (Pall Corporation) at 5000 g at 4◦C for 20 min
followed by a 10 min centrifugation at 13 000 rpm at 4◦C.
The concentrations were measured with a Nanodrop 2000
(Thermo Fisher) using the dialysis buffer as blank. The
ITC experiment was performed using a MicroCal iTC200
(Malvern Instruments) at 35◦C with 10 M of protein in
the 200 l sample cell and 40 l of 70 M Prox1-DNA
in the syringe. The protein concentration was adjusted to
10 M using the Prox1-DNA dialysate after overnight
dialysis. The titration was initiated with a 0.4 l initial
injection to minimize equilibration artifacts followed by
19 × 2 l injections in 80 s intervals. Experimental data
were corrected for the heat of dilution of the Prox1-DNA
into the solvent and analysed using OriginTM software. The
concentration of SOX18-HMG (79 aa) was corrected to
5.4 M of active protein, determined by an active fraction
experiment (Supplementary Figure S1).
Fluorescence resonance energy transfer (FRET) assay
To study SOX18-HMG box-induced DNA bending we
adopted procedures previously reported for the TBP/TATA
system (33). The SOX18-HMG (79 aa) and several dye-
modified 15-bp Prox1-DNA elements were prepared in-
cluding a donour-only control (DO, single 5′ cy3 label),
acceptor-only control (AO, single 5′ cy5 label) and a 5′
cy3/cy5 double labelled (DL) element. Every measurement
was done in triplicates and included a buffer control and
six reactions: (i) 60 nM DO DNA with and (ii) without
500 nM SOX18-HMG, (iii) 60 nM AO DNA with and (iv)
without 500 nM SOX18-HMG, (v) 60 nM DL DNA with
and (vi) without 500 nM SOX18-HMG in 30 l 1× fluo-
rescence resonance energy transfer (FRET) buffer (10 mM
Tris–HCl pH 8.0, 5 mM MgCl2, 50 mM KCl and 10% glyc-
erol). Reactions were set up in NUNC 384-well black bot-
tom plates (Thermo Fisher) and incubated at RT for 1 h.
Spectra were recorded using a Varioskan LUX Platereader
(Thermo Fisher) and two measurements were made: (i)
donor excitation at 535 nm with 555–720 nm emission scan
and (ii) acceptor excitation at 635 nm with 655–720 nm
emission scan. Dye-to-dye distances were calculated using
single point measurements at 567 nm for the donor and 668
nm for the acceptor emission (33). The association kinetic
was measured using 668 nm acceptor emission and imme-
diately after the protein (500 nM final concentration) was
added to the DNA (60 nM final). Dissociation kinetic was
measured by adding 1800 nM unlabelled Prox1-DNA to the
reaction. The dead time of the experiment was 20 ms and
readings were taken in 10 ms (association) or 40 ms (disso-
ciation) intervals. On-rates were calculated using equation
kon = (kobs-koff)/cprot where kobs is the observed association
rate, koff the observed dissociation rate per second and cprot
the molar protein concentration. To measure kobs and koff
averaged association and dissociation data from 40 inde-
pendent readings were modelled as single exponential rise
or decay as described (34). The equation Kd = koff/kon. was
used to calculate the binding constant (Kd).
Decoy DNA elements used
A 15-bp element was used for decoy design
CTAGCATTGTCTGGG (SOX motif underlined) in-
cluding a mutant control CTAGCAGGCTCTGGG. A
circular SOX decoy version where hexaethylene glycol
linkers covalently connect the 3′ and 5′ ends of the dsDNA
(‘CIRC’), a decoy with phosphorothioated internucleotide
linkages at the three terminal nucleotide pairs on either
end of the DNA element (‘PS’), a decoy version where
the PS modification and the circularization are combined
(‘PSCIRC’) and a decoy variant where all nucleotides
contain a 2′ O-methyl base (‘MEO’) were selected. PS
mutant and PSCIRC mutant contain the same motif as the
native (’NAT’) mutant control. CIRC, PSCIRC, PSCIRC
mutant, MEO (Integrated DNA Technologies), NAT, PS,
NAT mutant, PS mutant (Life technologies) were obtained
as powder, re-suspended in DNase and RNase-free deion-
ized water (TIANGEN) and annealed in 1× annealing
buffer as described above. The CIRC and PSCIRC decoys
were supplied with internal nick leaving a free 3′-OH and
5′-monophosphate between the central TT dinucleotide
and ligation was carried out after annealing using a T4
DNA ligase (NEB). Ligation mix was incubated at 16◦C
overnight, the enzyme was deactivated at 60◦C for 1 h and
pelleted by centrifugation at 13 000 rpm in a bench-top
centrifuge for 10 min. Decoys were stored at −20◦C until
usage.
Electrophoretic mobility shift assays (EMSAs)
5′-cy5 labelled DNA was used for electrophoretic mobility
shift assays (EMSAs). In preparation for the decoy compe-
tition assays the minimal protein concentrations required
to ensure complete supershifts of DNA were determined
for SOX-familiy proteins purified as described previously
(28) and other unrelated TFs produced for previous studies
along with their cognate DNA elements: PAX9 (35), OCT6
(36), ESRRB (37) (Supplementary Table S2). Proteins were
used at varying concentrations (16.6, 31.3, 62.5, 125, 250,
500, 1000 nM). The following concentrations were used for
decoy competition experiments: 100 nM of mouse SOX2-
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nM of his-tagged mouse SOX6-HMG (79 aa), 50 nM mouse
SOX18-HMG (109 aa or 79 aa), 80 nM of mouse SOX10-
HMG (79 aa), 100nM of mouse SOX17-HMG (79 aa), 100
nM of mouse ESRRB, 200 nM of mouse OCT6-POU or
BRN2-POU domain and 1 M of mouse PAX9. All re-
actions were incubated for 1.5 h at 4◦C with 20 nM cy5-
labelled DNA in EMSA buffer (10 mM Tris–HCl pH 8.0,
0.1 mg/ml bovine serum albumin, 50 M ZnCl2, 100 mM
KCl, 10% Ultrapure Glycerol, 0.10% NP-40, 2 mM BME).
Next, 20 l samples were loaded onto 15% (w/v) 1× Tris-
glycine (TG) polyacrylamide gels pre-run at 100 V in 1×
TG buffer (25 mM Tris, pH 8.3, 192 mM glycine) and elec-
trophoresed at 200 V for 30 min at 4◦C in the dark. The
gels were visualized using a FLA-7000 image reader (FUJI-
FILM). The ImageQuant TL Software (GE Healthcare Life
Sciences) was used to quantify the fraction of bound DNA
and IC50 values were estimated using non-linear regression
methods and custom R scripts.
Fluorescence polarization
Fluorescence polarization (FP) competition experi-
ments were carried out with a 5′-6-carboxyfluorescein
(FAM) labelled Prox1-DNA (5′-GGTTCCCCCGC
CCCCAGACAATGCTAGTTTGCATACAAAG, core
15 bp element underlined). A total of 2 nM FAM-dsDNA
was mixed with 160 nM SOX18-HMG box (109 aa) and
decoys were added at different concentrations (3.9, 7.8,
15.6, 31.3, 62.5, 125, 250, 500 nM) in reaction buffer (20
mM Tris–HCl pH 8.0, 100nM NaCl, 0.01% NP-40) to
a final reaction volume of 30l in a black 384-well plate
(NUNC, Yuwei). After incubating for 1 h at 25◦C plates
were centrifuged at 1800 g for 1 min and readings were
taken using the Wallac 1420 multilabel counter (Perkin
Elmer) with 480/535 nm wavelengths. Readings were
performed in triplicates.
Thermal stability assay
The decoy concentrations were adjusted to 1 M in TE
buffer (10 mM Tris pH 8.0, 1 mM ethylenediaminete-
traacetic acid (EDTA)). The solutions were placed into a 1
ml Varian quartz cuvette at a volume of 500 l. All five de-
coys and a TE buffer blank were analysed side-by-side using
a temperature regulated Cary 100 UV-Vis spectrophotome-
ter (Varian, South East Chemicals & Instrument Ltd). The
absorbance at 260 nm was monitored from 25◦C to 90◦C
(1◦C/min heating rate).
Serum stability assay
Mouse serum was obtained from mouse orbital blood by al-
lowing the blood to clot at RT for 15 to 30 min followed by
centrifugation at 1500 g for 10 min at 4◦C. The supernatant
was transferred into a PCR tube and stored at −20◦C until
further use. A total of 6 l of each decoy stock was added
to 44 l mouse serum to a final decoy concentration of 0.05
g/l. The reaction mix was incubated at 37◦C in a water
bath. At different time points (0, 1, 2, 4, 6, 8, 10, 36 h), 3
l were removed and placed into a 1.5 ml tube containing 3
l of 2 × formamide loading buffer (90% formamide, 0.5%
EDTA, 0.1% Xylene cyanol, 0.1% Bromphenol Blue). The
samples were kept on ice until loading onto the gel. After
heating the samples to 60◦C for 10 min they were loaded
onto a pre-run denaturating 15% polyacrylamid gel con-
taining 7 M urea and electrophoresed at 60 V for 2 h. The
gel was stained for 10 min with 1× SYBR Gold nucleic acid
gel stain (Invitrogen) in the dark and visualized under UV
light (Tanon 1600 Gel Imaging System).
DNase I resistance assay
A total of 0.05 g/l of each decoy was incubated at 37◦C
in a final reaction volume of 50 l containing 0.1 U DNase
I in 1× DNase I buffer (NEB). At different time points (0,
2, 4, 6, 10, 20, 40, 60, 120 and 180 min), 3 l of the reaction
mix were combined with 3 l 2× formamide loading buffer,
heated and electrophoresed as described above.
VCAM-1 luciferase reporter assay
COS7 cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM, Life Technologies) with 10% fetal
bovine serum (FBS, Biowest) in 24-well plates and grown
for 24 h to 80–90% confluency. Decoys, 200 ng VCAM1
Luciferase Reporter plasmid (38), 50 ng mouse SOX18 ex-
pression vector (38) and 1 ng pRL-SV40 Renilla expression
plasmid dissolved in OptiMEM (Invitrogen) were trans-
fected using X-tremeGENE 9 DNA Transfection Reagent
(Roche). As a negative control one set of samples was
transfected with the reporter and the pRL-SV40 plasmid
only. After incubating at 37◦C, 5% CO2 for 48 h the cells
were carefully washed with Dulbecco’s Phosphate Buffered
Saline (Gibco) and lysed in 100 l 1× Passive Lysis Buffer
(Promega). The lysate was stored at −80◦C until measure-
ments. Luciferase and Renilla activity were measured us-
ing Dual Luciferase Reporter System (Promega) and a Ver-
itas Microplate Luminometer (Turner Biosystems) follow-
ing the manufacturer’s protocols.
Quantitative reverse transcription PCR
COS7 cells were grown in DMEM + 10% FBS for 24 h to
60% confluency in a 48-well plate and then transfected with
X-tremeGENE 9 DNA transfection reagent (Roche) with 1
M PSCIRC decoy or with water, 2 ng pRL-SV40 (Renilla
plasmid), 50 ng Sox18 expression vector and 200 ng VCAM
reporter plasmid. RNA were collected after 48 h of trans-
fection with TRIzol R© Reagent (Life Technologies) then ex-
tracted using isopropyl alcohol precipitation. RNA concen-
tration was measured by Nanodrop 2000 (Thermo), 2 g of
RNA was reverse transcribed using ReverTra Ace (Toyobo)
for 60 min at 42◦C and 99◦C for 5 min. cDNA was diluted
1:80 for each experiment and qPCR was performed using
a CFX96 device (Bio-Rad) with iTaqTM Universal SYBR R©
Green Supermix (Bio-Rad). The primers are listed in Sup-
plementary Table S3. Raw data were transformed using the
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Figure 1. Calorimetry, DNA deformation and kinetics of SOX18-HMG/Prox1-DNA complex formation. (A) Calibrated size exclusion chromatogram of
79 aa and 109 aa versions of the SOX18-HMG showing that the proteins elute as symmetrical peaks corresponding to the molecular weight of the respective
monomers. The grey curve is a molecular weight standard with weights indicated in kDa. (B) Representative ITC titration of 70 M 15-bp Prox1-DNA
in the syringe and 10 M SOX18-HMG (79 aa) in the cell. The lower panel shows the equilibrium isotherm and the inset the parameters obtained using
single site binding models and the Origin software. (C) FRET spectra of 15 bp Prox1-DNA labelled with 5′ cy3 at the forward and 5′ cy5 at the reverse
strand before (blue) and after (black) addition of the SOX18-HMG. Spectra were recorded from 555–720 nm after excitation at 535 nm for double labelled
(C) or single labelled Prox1 elements (D and E). The Association (F) and the dissociation (G) kinetics of SOX18 with Prox1 were measured by recording
the cy5 (FRET acceptor) emission at 668 nm. Red curves are mono-exponential fits to the data.
RESULTS
In solution analysis of SOX18/Prox1-DNA interaction
To study DNA recognition by SOX18, 79 and 109 amino
acid SOX18-HMG box protein constructs were overex-
pressed and purified to homogeneity. Both constructs eluted
from size exclusion columns at a volume consistent with
monomeric proteins (Figure 1A). For binding assays a
15-bp Sox18-binding site regulating the expression of the
Prox1 gene was selected. It has previously been reported
that sequence-specific HMG boxes are partially unfolded
and refold upon DNA complex formation accompanied by
a considerable heat effect (39). These heat effects can be
measured calorimetrically and we therefore performed ITC
with SOX18-HMG (79 aa) and Prox1-DNA. As expected,
we observed strong exothermic signals at 35◦C with a H
= −42.9 kcal/mol, indicating HMG box refolding and ef-
fective SOX18/Prox1 complex formation (Figure 1B). Sur-
prisingly, the association constant Ka derived from our ITC
measurements was only 2.47 × 106 ± 5.97 × 105 M−1,
which deviates from previously reported affinity measure-
ments carried out with alternative methods (26,39–40). This
is likely because these measurements do not distinguish be-
tween heat effects upon HMG box refolding and heat ef-
fects of association (39). We therefore went on to study
SOX18/Prox1-DNA binding using optical methods that
are not sensitive to temperature changes. The DNA bend-
ing by HMG boxes can be detected in solution by moni-
toring changes of FRET signals using end-labelled DNA
(39). We established this assay for the SOX18/Prox1-DNA
binding system and observed a substantial increase of the
acceptor emission with concurrent decrease of the donor
emission when SOX18 was added to Prox1-DNA (Figure
1C). This observation is due to FRET and not caused by
FRET-independent changes of the fluorescence intensities
upon SOX18 binding (Figure 1D and E). This finding indi-
cates a pronounced reduction of the distance between the








ong Kong user on 15 February 2019
Nucleic Acids Research, 2016, Vol. 44, No. 8 3927
Figure 2. Structure of the SOX18-HMG/Prox1-DNA complex. (A) Sequence of the SOX18-HMG construct used. Numbering follows the convention
used for HMG boxes (1) and does not refer to the full length protein. The N-terminal glycine marked in red is a relict of the TEV protease site and H1-H3
denote the three alpha-helices. (B) Final model of the SOX18/Prox1-DNA complex with DNA shown as ball-and-sticks and the protein as cartoon. Helices
H1-H3 are shown as cylinders and N-and C-termini are marked. The sequence of the Prox1 element with CG overhangs used for crystallization is depicted
below. The core Sox binding site is boxed. (C–E) Snapshots of the final 2Fo-Fc electron density contoured at 1.5  (C and D) or 1.0 (E) and carved at 1.8
Å around the selected atoms. The position of the displayed nucleotides within the Prox1 element is marked with red letters. (C and D) show specific base
contacts including interface waters (C) and (E) shows the interaction of Arg2 with a backbone phosphate adopting a non-canonical conformation.
binding from 57.8 to 49.0Å. Next, the FRET assay was
adopted to study the kinetics of the SOX18/Prox1 inter-
action. The complex formation is driven by fast associa-
tion kinetics with an association constant kon 1.02 ± 0.06
× 107 (M−1 × s−1) (Figure 1F). By incubating with an ex-
cess of unlabelled competitor, the dissociation constant koff
was measured to be 0.062+/− 0.001 (s−1) corresponding to
a binding constant Kd = koff/kon = 6.1 × 10−9M (Figure
1G). This value is in good agreement with previously mea-
sured affinities for SOX-HMG boxes using EMSAs (26) and
SRY binding to its cognate DNA binding element by FRET
(40). Collectively, these experiments indicate a fast, stable
and functional interaction of SOX18 with the Prox1-DNA
fragment accompanied by pronounced DNA bending.
Overall structure of the SOX18/Prox1-DNA complex
To investigate the SOX18/Prox1-DNA interactions at
atomic resolution, extensive screening for suitable crystal-
lization conditions was carried out. A 16-bp Prox1-DNA
element containing CG overhangs and the SOX18-HMG
box (79 aa) construct was found to be most suitable for the
growth of well-diffracting crystals (Figure 2A and B, Sup-
plementary Figure S2). A high resolution 1.75 Å dataset
was collected, the structure was determined by molecu-
lar replacement and could be refined to R/Rfree factors of
17.4/19.9% (Supplementary Table S1).
The SOX18-HMG box consists of a three-helix bundle
exhibiting an L-shaped structure with the long arm com-
posed of helix 3 and the short arm of helices 1 and 2 (Fig-
ure 2A and B). The N-terminus (residue 1–9, amino acid
numbering according to HMG conventions (1)) and the
C-terminus (residue 66–75) adopt extended conformations
and interlace approximately orthogonally. Binding occurs
exclusively in the minor groove of the DNA. The DNA
is located in the concave face of the HMG domain and
the conformation of the DNA follows the contours of the
concave binding surface. In this article we will refer to
the following numbering scheme of the core SOX motif
G1C2A3T4T5G6T7C8 and define the reverse complement
sequences in a 3′-5′ direction as C’1G2’T3’A4’A5’C6’A7’G8’
(Figure 2B). The C-terminal amino acids of the SOX18-
HMG 76–79 and the 3′ ‘T’ of the reverse strand could not
be traced in the electron density map and were omitted
from the final model. The remainder of the complex shows
electron density of high quality (Figure 2C–E). In particu-
lar the protein–DNA contact interface is well defined and
reliably reveals details including water molecules (Figure
2C) and unambiguously allows the placement of side-chains
that were only moderately well defined in previous lower
resolution structures, e.g. Tyr72 (Figure 2D, Supplemen-
tary Figure S3). Moreover, the phosphodiester backbone at
A5’ is found to adopt a non-canonical gauche+/trans con-
figuration having the  angle (O3*(-1)-P-O5*-C5* = 65◦)
and the  torsion angle (O5*-C5*-C4*-C3* = 174◦) (Figure
2E). The majority of nucleotides adopt a gauche−/gauche+
configuration but gauche+/trans is found in less than 2.4%
of analysed nucleotides (41). A5’ is contacted by Arg2 which
likely abets the gauche+/trans conformation. Therefore, the
conformation of the A5′C6′ backbone could contribute to
an ‘indirect readout’ mechanism and indicate that selective
binding at this position is dictated by DNA shape rather
than by complementary hydrogen bonding between inter-
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Figure 3. SOX proteins induce conserved bends and rearrange to accommodate variant DNA elements. (A) Helical axis calculated by Curves+ (43) used to
estimate the total bend for SOX2 (PDB ID: 1gt0), SOX4 (3u2b), SOX9 (4euw), SOX17 (3f27) and SOX18 (this study). All five SOX/DNA complexes show
a similar overall bend between 60◦ and 70◦ (Supplementary Table S4). The inter base-pair parameters roll angle (B) and twist angle (C) were calculated
using Curves+ (43) and plotted against the DNA sequence. The x-axis shows the forward strand of the Prox1-DNA sequence co-crystallized with the
SOX18-HMG. (D) Tube representation of the SOX18-HMG highlighting the conserved set of DNA-binding residues present in all 20 SOX TFs. DNA was
omitted and orientation was changed with respect to Figure 2B for optimized visibility. (E) Comparison of the conformation of His29 in SOX18 (slate blue)
and SOX4 (ruby red) and the G1C’1 base-pair (SOX18) which is converted into C1G1’ in the SOX4/DNA complex. (F) Conformational switch of Arg5
and Tyr72 in SOX18 (slate blue) and SOX9 (green) to accommodate the different environment provided by T7A7’ (SOX18) or A7T7’ (SOX9), respectively.
H-bonds are indicated with dashed lines. Displayed base pairs are highlighted in red in the core Prox1 elements used.
Comparing DNA bending and binding by different SOX TFs
The topology of SOX/DNA complexes could affect the as-
sembly of regulatory complexes and thereby influence gene
expression. We thus compared the structure of the DNA
elements co-crystallized with SOX18 and four other SOX
proteins. We first estimated the total bending angle us-
ing Curves+ (43) (Supplementary Table S4). Globally, the
DNA co-crystallized with SOX2, SOX4, SOX17, SOX18
and SOX9 exhibits very similar bending angles in the nar-
row range of 60–70◦ (Figure 3A). Locally, C2A3T4 show
the strongest deviations from the base-pair parameters of
canonical B-DNA (Figure 3B and C). In particular the
roll angle is increased at the site of the intercalation of
Phe10Met11 (between T4 and T5) but also at the two pre-
ceding base-pairs. Concurrently, unwinding of the double
helix is reflected in the reduced twist angles (Figure 3C).
The pattern and the magnitude of the changes to inter base-
pair parameters are very similar for all five SOX/DNA com-
plexes. Therefore, the DNA architecture induced by SOX
proteins is not profoundly affected by the exact sequence
of the DNA binding site nor by amino acid variations
between paralogous SOX proteins. Further, DNA struc-
ture is not markedly changed despite different crystalliza-
tion conditions, the presence of co-factor as in the ternary
SOX2/OCT1/DNA complex and different crystal packing
interactions that are mostly involving the DNA ends. Col-
lectively, this analysis suggests that the mechanism of DNA
bending is conserved throughout the SOX family and rather
insensitive to variations in DNA sequence.
We next inspected the DNA contact interface of the
five SOX proteins to identify structural difference. SOX
HMG boxes possess a core set of DNA contact residues
that are invariantly conserved amongst paralogues (Arg5,
Asn8, Phe10, Met11, Arg18, His29, Asn30, Ser34, Trp41
and Tyr72, Figure 3D). We have previously noted that the
side-chains of Arg18 and Asn30 re-orient in concert to ac-
commodate different DNA sequences (27). Here we found
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Figure 4. Modified SOX decoys potently inhibit DNA binding of SOX18. The potency to inhibit binding of 50 nM SOX18-HMG to 20 nM cy5-labelled
Prox1-DNA by three decoys was assessed by EMSAs using decoy concentrations 500, 250, 125, 60, 30, 15, 7.5, 3.75 nM. The left panel shows a scheme
of the decoys and a structural cartoon of the termini to illustrate the modifications. (A) Unmodified decoy ‘NAT’, (B) ‘PS’ decoy where asterisk and
yellow spheres indicate phosphorothioate modification sites and (C) ‘PSCIRC’ containing ‘PS’ modifications and an additional PEG linker connecting 3′
and 5′ ends. Central and right panels show quantifications of competition EMSAs with the fraction of bound cy5-labelled reported DNA on the y-axis
plotted against decoy concentration. IC50 values were estimated using non-linear curve fitting and a 4-parametric model. The IC50 value is shown and
the modelled curve is depicted in red. For all mutants the central TTG was replaced by a GGC sequence. Data points in the plots represent mean +/−
standard deviation of triplicate experiments. Representative EMSA gel images used for quantification are shown in Supplementary Figure S5.
acids engage DNA in the various SOX/DNA complexes.
For example, His29 forms a H-bond with N3 of G1′ in
the SOX4/Lama1 structure. However, this contact is lost in
SOX18 presumably because G1′ is replaced by C1’ in the
Prox1 sequence providing a less favourable chemical envi-
ronment (Figure 3E). Further, in SOX18 Tyr72 forms an
H-bond with the N3 of A7’ and Arg5 with the O2 of the
reverse complementary T7. By contrast, when the bases are
inverted, as in the DNA element co-crystallized with SOX9,
the side chains of Tyr72 and Arg5 concurrently reorient to
now interact with A7 or T7’, respectively (Figure 3F). We
conclude that the observed minor variations at SOX/DNA
contact interfaces reflect structural adjustment to accom-
modate different DNA sequences and are not indicative of
binding modes specific for individual SOX proteins (Sup-
plementary Figure S4A–C).
Decoy oligonucleotides potently inhibit the SOX18/Prox1-
DNA interactions
We have previously shown that polyanionic polyoxometha-
lates (POM) potently interfere with the DNA binding ac-
tivity of SOX proteins but even POMs with organic modi-
fications were found to be rather unselective and inhibited
a wide range of TF classes (44,45). We therefore decided
to explore whether DNA decoys can be designed to inhibit
the DNA binding activity of SOX18 with a better selectivity
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Figure 5. Decoys inhibit SOX but not unrelated TFs. (A) IC50 fit to competition EMSA data using the ‘CIRC’ decoy and the SOX18-HMG carried out as
for ‘NAT’, ’PS’ and ‘PSCIRC’ in Figure 4 with gel images in Supplementary Figure S5. Binding of ESRRB, OCT6 and PAX9 to their cy5-labelled cognate
DNA binding site (B) or of the SOX family members SOX18, SOX17, SOX2, SOX4, SOX6 and SOX10 (C) to the Prox1 DNA was challenged using the
CIRC decoy. The triangle above the EMSA images denotes 2-fold dilution series for the CIRC decoy (1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8). b and f
denote bound and free DNA, respectively. See Supplementary Figure S7 for PSCIRC data.
sion in which hexaethylene glycol linkers covalently connect
the 3′ and 5′ ends of the DNA (‘CIRC’). A similar modifi-
cation was used to design STAT3 decoys for phase 0 clinical
trials (46). Secondly, decoys with phosphorothioated inter-
nucleotide linkages at the three terminal nucleotide pairs on
either end of the DNA element were considered (‘PS’ mod-
ification (47)). Third, we opted for a decoy variant where all
nucleotides contain a 2′ O-methyl base (‘MEO’). The MEO
modification is widely used to stabilize RNA based thera-
peutics (48). Forth, the PS and the CIRC modifications were
used in combination (‘PSCIRC’). Modified DNA decoy ele-
ments were designed in silico using a 15-bp DNA and mod-
elled onto the SOX18/Prox1-DNA crystal structure. From
these models the modifications are not expected to directly
impair the binding by SOX18 (Figure 4). All decoys were
tested for their capacity to interfere with the binding activity
of the SOX18-HMG box to a cy5-labelled Prox1-DNA in
EMSAs (Figure 4, Supplementary Figure S5). As expected,
the unlabelled and unmodified ‘NAT’ decoy competed ef-
fectively with the labelled reporter whereas a mutant ele-
ment (‘NAT mutant’) barely showed inhibitory effects (Fig-
ure 4A). The PS, PSCIRC (Figure 4B and C) and CIRC
decoys (Figure 5A) inhibited reporter DNA binding simi-
larly as the NAT decoy (see also Supplementary Figure S5).
When mutations of the SOX binding sites were tested in the
context of the PS and the PSCIRC modifications, the IC50
increased by 40- or 4-fold, respectively (Figure 4B and C).
This suggests that the modifications relax the requirements
of SOX18 for its consensus-binding site.
The MEO modification leads to a drastic reduction of
the inhibitory potential and was excluded from further as-
says (Supplementary Figure S5). FP assays using FAM-
labelled reporter DNA showed an inhibitory profile con-
sistent with the EMSAs for all tested decoy modifications
(Supplementary Figure S6). Apparent IC50 values vary be-
tween EMSA and FP assays as different reporter DNA
and SOX18-HMG protein concentrations were used to en-
sure satisfactory signal-to-noise ratios of both assays. Col-
lectively, PS, CIRC and PSCIRC decoys represent DNA
modifications that retain high-affinity interactions with the
SOX18-HMG box.
Modified decoys specifically interfere with DNA binding of
the SOX transcription factor family
We have previously encountered difficulties in identifying
small molecule compounds that show a satisfactory selec-
tivity profile (44). To probe whether SOX decoys bind to
other TFs, we tested the inhibition of several non-SOX TFs
that represent a set of structurally diverse DNA binding do-
mains. The orphan nuclear receptor ESRRB, the paired do-
main protein PAX9 and the highly homologous POU do-
mains of OCT6 and BRN2 were selected. We used CIRC
and PSCIRC decoys that effectively bind to SOX18 for
these experiments (Figures 4C and 5A). CIRC and PSCIRC
do not inhibit DNA binding to cognate DNA elements
by ESRRB, PAX9 and OCT6 at concentrations up to 500
nM while unlabelled competitors for these proteins encod-








ong Kong user on 15 February 2019
Nucleic Acids Research, 2016, Vol. 44, No. 8 3931
such concentrations (Figure 5B, Supplementary Figure S7).
Next, decoy binding to members of the SOX family was
tested using members from all major SOX subfamilies in-
cluding SOX2 (SOXB1), SOX4 (SOXC), SOX6 (SOXD),
SOX10 (SOXE) and SOX17 which as SOX18 belongs to the
SOXF family. Results show that the CIRC and PSCIRC de-
coys effectively inhibits DNA binding by all SOX factors
(Figure 5C, Supplementary Figure S7).
Modified SOX decoys enhance stability and interference with
transcriptional regulation
A key limitation for the application of decoys as research
tools or therapeutics is their rapid degradation in a cellu-
lar environment or in the blood. We therefore conducted a
series of experiments to assess the stability of the SOX de-
coys. First, the decoys were incubated in mouse serum and
their time dependent integrity was monitored using urea-
PAGE and SYBR Gold staining (Figure 6A). We found that
all tested modifications increased the resistance to degrada-
tion in mouse serum with PSCIRC remaining intact even
after 36 h of serum exposure. Second, their stability in the
presence of DNase I was tested (Figure 6B). The PSCIRC
decoy was observed to be most resistant to DNase I degra-
dation whereas other decoys showed only marginal stability
improvements against this endonuclease activity. Third, by
measuring the absorbance at 260 nm versus temperature the
thermal stability of the decoys was assessed. We observed
that the PS modification caused a reduction in the thermal
stability compared to the unmodified DNA (Figure 6C). By
contrast, the CIRC decoy substantially delayed thermal de-
naturation. Moreover, the circularization rescued the heat
sensitivity of the PS modification illustrated by the post-
poned melting of the PSCIRC variant.
We next studied whether SOX decoys can disrupt SOX18-
mediated transcriptional activity in a cellular environment
using a reporter assay where the luciferase gene is under
the control of an 1889-bp promoter region of the vascu-
lar cell adhesion molecule-1 (VCAM-1) gene to which the
SOX18 protein binds (Figure 6D) (38). The COS7 cell line
was chosen for these experiments, as SOX18 is not nor-
mally expressed in this cell type. We first reaffirmed that
SOX18 is necessary for the transcriptional upregulation
of the reporter in a dose-dependent manner (Figure 6D).
Next, we tested the inhibitory effects using 50 ng of SOX18
plasmid of the studied decoys side-by-side at 1 M con-
centration 48 h post-transfection (Figure 6E). All decoys
were found to exert some noticeable inhibitory activity. Yet,
the PSCIRC inhibited transcription most potently and re-
duced the luciferase expression by ∼40% as compared to
the vehicle control (no decoy). The inhibitory effect was
also observed at lower PSCIRC concentrations (Figure 6F).
The expression of control genes was not perturbed upon
PSCIRC treatment indicating that PSCIRC does not glob-
ally interfere with transcription (Figure 6G). This finding is
in accordance with the stability assays and suggests that the
stability-enhanced PSCIRC decoy possesses the best prop-
erties to interfere with SOX18 activity in a cellular environ-
ment.
DISCUSSION
SOX proteins act as master regulators mediating cellu-
lar reprogramming and dictate multiple cell fate decisions.
They often maintain multipotential progenitor states and
stem cell-like phenotypes, e.g. SOX2. These properties likely
underlie the competence of many SOX proteins to drive
tumorigenesis. For example, SOX4 contributes to acute
myeloid leukemia (49) and prostate cancer (50). Further,
SOX2 reprograms cancer cells and maintains their stem-
like properties (51,52) and SOX10 initiates and maintains
melanomas (53). Thus, technologies that enable direct in-
terference with SOX proteins in such pathological situations
would be hugely beneficial not only as potential therapy but
also as research tools. However, the DNA-binding HMG
box is thus far the only structurally analysed portion of SOX
proteins and while regions outside the box have been func-
tionally annotated as transcriptional activators and dimer-
ization elements (2), it is unclear whether such regions rep-
resent globular domains that fold independently of interact-
ing proteins. Therefore, the HMG box currently represents
the only tractable structural target for therapeutic interven-
tion. However, targeting the DNA recognition interface of
TFs using conventional small molecules is notoriously chal-
lenging, as hydrophobic pockets that could easily accom-
modate such compounds are virtually absent.
Here, we explored a DNA decoy approach as an alter-
native avenue for SOX inhibition. We focused on SOX18
because of its role in initiating tumour-induced neo-
lymphangiogenesis paving the way for subsequent tumour
metastasis (16). TF decoys are short double stranded DNA
sequences encoding cognate binding sequences of TFs
(47,54). This way, TFs are sequestered in the nucleus or
the cytoplasm preventing them from regulating their tar-
gets and gene expression programs leading to tumorigen-
esis are thereby suppressed. First proof-of-principle studies
were carried out with decoys targeting the TF E2F (55–57).
To develop nucleic acid into therapeutics a number of road-
blocks are to be removed: challenging pharmacokinetics,
delivery to the target tissue and cellular uptake. Neverthe-
less, antisense drugs based on modified RNAs that received
regulatory approval for systemic delivery provide tailwinds
for nucleic acid based therapeutics (58). Moreover, DNA
decoys targeting different classes of TF proteins have been
advanced into different stages of clinical trials including
decoys targeting E2F to prevent bypass vein graft failures
(56,59), EGR1 to treat various forms of pain (60), STAT3
in head and neck tumours (46) and the anti-inflammatory
NF-B protein (61,62).
In this study, we present a high-resolution crystal struc-
ture and used the structural models to design SOX decoys
based on the DNA sequence of the cognate SOX18 bind-
ing site controlling the expression of Prox1. A novel inno-
vative DNA circularization strategy developed for STAT3
decoys enabled systemic delivery in human (46). We com-
bined this circularization approach with the more classi-
cal phosphorothioation and demonstrated that SOX decoys
potently inhibit the DNA binding of all SOX proteins but
not of unrelated TFs. Encouragingly, the stability-enhanced
PSCIRC decoy interferes with SOX18-mediated transcrip-
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Figure 6. Modified SOX decoys show enhanced stability and repress reporter gene transactivation. (A) Decoys were incubated in mouse serum and their
integrity was assessed by urea-PAGE and SYBR gold nucleic acid staining as a function of incubation time. The ‘0’ lane marks a sample taken immediately
after mixing with serum and numbers denote time in hours. UD: undigested decoys. SO: serum only. (B) Decoys were incubated with DNase I and analysed
as in (A). (C) The melting of decoys was monitored by heating 1 M DNA to 90◦C at 1◦C/min and recording the absorbance at 260 nm. (D) SOX18
exogenously expressed in COS-7 cells activates the expression of a luciferase reporter under control of a regulatory region derived from the VCAM-1 gene
(38) in a dose-dependent manner. The inlet illustrates the assay set-up. (E) The effect of decoys at 1000 nM on the VCAM-1 reporter activity was compared
48 h post-transfection using 50 ng of SOX18 plasmid. (F) Effects of the PSCIRC on luciferase expression at different concentrations. (G) Expression of
selected genes detected by RT-qPCR in the absence or presence of the PSCIRC. The mean and standard deviation from three experiments each carried out
in triplicates is shown. The asterisks (**) denote P < 0.001 (t-test).
a viable approach to target SOX18 and other SOX proteins.
One remaining challenge remains to invent decoy modifica-
tions that selectively bind to only SOX18 but not to other
SOX HMG boxes. It has recently been reported that decoys
that discriminate between the closely related paralogous
TFs STAT1 and STAT3 could be designed with rational nu-
cleotide substitutions (63). However, our structural analysis
revealed a virtually identical set of DNA contacting amino
acids shared by all SOX proteins (Figure 3D). We there-
fore inspected the SOX18/Prox1-DNA structure in search
of structural elements not directly involved in DNA recog-
nition that could permit the design of specific SOX18 de-
coys. We reasoned that Val32, at the start of helix 2, provides
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Figure 7. Engineering a SOX18-selective decoy. (A) Valine 32 of SOX18 maps to a region proximal to the phosphodiester connecting nucleotides C2 and
A3. Only SOX18 possesses an aliphatic valine at position 32 but SOX17 and many other SOX proteins contain an acidic glutamate (B and C). Valine 32
is evolutionarily conserved amongst SOX18 orthologs but unique within the SOX family (C).
selective decoys (Figure 7A). First, Val32 is located close
to the phosphodiester bond connecting C2 and A3 (Figure
7A). Second, only SOX18 contains an aliphatic valine at po-
sition 32 whereas most other SOX proteins, including the
closely related SOXF factors SOX7 and SOX17, encode an
acidic glutamate (Figure 7B and C). Third, Val32 is highly
conserved amongst orthologous SOX18 proteins suggesting
functional relevance (Figure 7C). Thus, we propose Val32
as a selectivity hotspot that could provide an avenue to de-
sign SOX18-selective decoys. As Val32 is positioned too re-
mote from actual nucleobases, nucleotide substitutions are
unlikely to contribute to selectivity improvements. Rather,
derivatization of the phosphate backbone itself with amino
acids and other organic moieties via a phosphotriester link-
age presents a promising strategy. The general feasibility
of this approach has recently been demonstrated for RNAi
prodrugs where neutral phosphotriester groups augmented
cellular delivery (64). To further substantiate this idea we
performed structural modelling and covalently attached a
proline derivative (2-pyrrolidinecarbothionic S-acid) to the
phosphate backbone proximal to Val32 (Supplementary
Figure S8). After energy minimization, the proline residue
makes a favourable hydrophobic contact with Val32. By
contrast, this modification causes the acidic side-chain of
Glu32 present at equivalent positions in SOX17 or SOX4
to reorient suggesting an impairment of the interaction. We
therefore suggest that modification of the decoy backbone
with organic moieties present a promising strategy to engi-
neer SOX18-selective decoys. Collectively, we propose SOX
decoys as a potential strategy for inhibiting SOX18 activity,
an approach which upon further development could open
up new therapeutic avenues to counteract tumour-induced
neo-lymphangiogenesis and associated cancer metastasis.
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